Payment overview · 2025
General Payments
$361.12
12 reported records · 6 companies
Healthcare provider profile · identity verified
Jayaram Naidu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ODESSA, TX · NPI 1710954292
Verified facts
What the public records show
CMS Open Payments records show Jayaram Naidu, MD received $361.12 in general payments during 2025 across 12 reported records.
Travere Therapeutics, Inc. accounted for 34.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 34.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $105.61 | 29.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.01 | 11.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $39.11 | 10.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.28 | 6.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$24.11 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $361.12 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $79.13 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $69.49 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.57 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 418 | 116 |
| Metoprolol Succinate | Metoprolol Succinate | 265 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 83 |
| Losartan Potassium | Losartan Potassium | 260 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 255 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 85 |
| Gabapentin | Gabapentin | 192 | 56 |
| Lisinopril | Lisinopril | 187 | 54 |
| Azithromycin | Azithromycin | 164 | 100 |
| Glimepiride | Glimepiride | 153 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 47 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 103 | 25 |
| Furosemide | Furosemide | 102 | 42 |
| Allopurinol | Allopurinol | 100 | 29 |
| Mounjaro | Tirzepatide | 96 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 28 |
| Metformin Hcl | Metformin Hcl | 76 | 28 |
| Simvastatin | Simvastatin | 76 | 17 |
| Temazepam | Temazepam | 75 | 17 |
| Eliquis | Apixaban | 73 | 21 |
| Clonidine Hcl | Clonidine Hcl | 70 | 26 |
| Prednisone | Prednisone | 70 | 26 |
| Ezetimibe | Ezetimibe | 69 | 22 |
| Sertraline Hcl | Sertraline Hcl | 65 | 18 |
| Alendronate Sodium | Alendronate Sodium | 62 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 20 |
| Omeprazole | Omeprazole | 58 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 17 |
| Ozempic | Semaglutide | 54 | 11 |
| Trazodone Hcl | Trazodone Hcl | 54 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 52 | 18 |
| Spironolactone | Spironolactone | 52 | 19 |
| Alprazolam | Alprazolam | 50 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 13 |
| Carvedilol | Carvedilol | 46 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | 11 |
| Farxiga | Dapagliflozin Propanediol | 45 | 15 |
| Montelukast Sodium | Montelukast Sodium | 45 | 15 |
| Fluconazole | Fluconazole | 43 | 14 |
| Meloxicam | Meloxicam | 42 | 14 |
| Tramadol Hcl | Tramadol Hcl | 41 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 27 |
| Donepezil Hcl | Donepezil Hcl | 40 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 18 |
| Potassium Chloride | Potassium Chloride | 38 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 11 |
| Finasteride | Finasteride | 35 | 13 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 11 |
| Buspirone Hcl | Buspirone Hcl | 33 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | 11 |
| Bumetanide | Bumetanide | 31 | 15 |
| Methocarbamol | Methocarbamol | 31 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Metolazone | Metolazone | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Fasenra Pen | Benralizumab | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $361.12 · 12 records | Travere Therapeutics, Inc. | FARXIGA, Filspari, JARDIANCE, MINIMED 780G, MOUNJARO, TEZSPIRE, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error